Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Trey Yon who wrote (568)	5/13/2000 6:04:00 PM
From: Vector1	Read Replies (1) \| Respond to of 666

Trey, Thanks. I am very much a fundamental long term investor. Sometimes to a fault. I can be very stubborn. CLTR is an example. I sold very few shares when the stock was in the 40s and had a feeling when the biotech correction started that CLTR was bound to follow. However, I continue to believe that Bexxar is an approvable drug with sales potential in excess of $400m. It is imo more efficacious that Rituxan and Zev and has fewer side effects than Zev. I am completely frustrated and bewildered by the company's inability to sucessfully file their BLA. Either the company is imcompetant in this area or the FDA has been criminally negligent in creating a bureaucratic nighmare for the company thereby keeping a life saving drug from sick patients. I would love to see the WSJ or some news magazine investigate. I do not put any value in the patent claim against Zev. I think CLTR has blocking rights with respect to the use of a radiolabeled antibody for dosemitry. I do not beleive CLTR will prevail in an attempt to block Zev. However, I believe there is a good chance that Zev is not approvable. The stock should be bought because Bex is the best molecule avialable for low grade, transforming and intermediate NHL. V1